<strong>Purpose:</strong> This study aimed to evaluate the role of <sup>18</sup>F-FDG PET/CT scans in staging breast carcinoma. <strong>Materials and Methods:</strong> A descriptive...<strong>Purpose:</strong> This study aimed to evaluate the role of <sup>18</sup>F-FDG PET/CT scans in staging breast carcinoma. <strong>Materials and Methods:</strong> A descriptive study on 46 patients who were diagnosed with breast carcinoma in Hanoi Oncology Hospital, Vietnam from June 2019 to June 2021. Those patients underwent <sup>18</sup>F-FDG PET/CT scans for pre-treatment staging. <strong>Results:</strong> There was a positive correlation between the size of primary tumors and their SUV (p < 0.0001, r = 0.759). The mean SUV was reported to be 2.5 for tumors under 2 cm, 5.89 for tumors from 2 - 5 cm, 13.6 for tumors above 5 cm, and 8.23 for skin invasive lesions. In terms of regional lymph node metastasis detection, the sensitivity and specificity of <sup>18</sup>F-FDG PET/CT were 75% and 100%, respectively. The rate of distant metastasis detection was 15.2% (7/46 patients). Metastatic lesions were found in bone, lungs, liver, and lymph nodes. There was a significant difference in SUV among organs (p < 0.001), with the highest SUV found in bone metastasis. The rates of stage I, II, III and IV diagnosed after PET/CT are 8.7%;45.7%;30.4% and 15.2% respectively, compared to 10.9%;54.3%;32.6%;2.2% before taking <sup>18</sup>F-FDG PET/CT. After PET/CT, 17.4% patients (8/46) had their treatment plan changed. <strong>Conclusions: </strong><sup>18</sup>F-FDG PET/CT plays an important role in staging breast carcinoma. Determining accurately the breast carcinoma stage by <sup>18</sup>F-FDG PET/CT could help alter treatment strategy to best suit with patients, and avoid unnecessary surgery.展开更多
文摘<strong>Purpose:</strong> This study aimed to evaluate the role of <sup>18</sup>F-FDG PET/CT scans in staging breast carcinoma. <strong>Materials and Methods:</strong> A descriptive study on 46 patients who were diagnosed with breast carcinoma in Hanoi Oncology Hospital, Vietnam from June 2019 to June 2021. Those patients underwent <sup>18</sup>F-FDG PET/CT scans for pre-treatment staging. <strong>Results:</strong> There was a positive correlation between the size of primary tumors and their SUV (p < 0.0001, r = 0.759). The mean SUV was reported to be 2.5 for tumors under 2 cm, 5.89 for tumors from 2 - 5 cm, 13.6 for tumors above 5 cm, and 8.23 for skin invasive lesions. In terms of regional lymph node metastasis detection, the sensitivity and specificity of <sup>18</sup>F-FDG PET/CT were 75% and 100%, respectively. The rate of distant metastasis detection was 15.2% (7/46 patients). Metastatic lesions were found in bone, lungs, liver, and lymph nodes. There was a significant difference in SUV among organs (p < 0.001), with the highest SUV found in bone metastasis. The rates of stage I, II, III and IV diagnosed after PET/CT are 8.7%;45.7%;30.4% and 15.2% respectively, compared to 10.9%;54.3%;32.6%;2.2% before taking <sup>18</sup>F-FDG PET/CT. After PET/CT, 17.4% patients (8/46) had their treatment plan changed. <strong>Conclusions: </strong><sup>18</sup>F-FDG PET/CT plays an important role in staging breast carcinoma. Determining accurately the breast carcinoma stage by <sup>18</sup>F-FDG PET/CT could help alter treatment strategy to best suit with patients, and avoid unnecessary surgery.
